During a dedicated event held on the opening day of its 2018 Annual Meeting, the American Association for Cancer Research (AACR) presented an award to a researcher from Nerviano Medical Sciences.
Elena Ardini, a biologist at Nerviano Medical Sciences, is the first author of a scientific publication that qualified for entry into the "Best of the AACR Journals Collection", a compilation of the most read and cited articles published in the Association’s Journals.
The article by Elena and her colleagues describes preclinical biology studies performed on Entrectinib, a kinase inhibitor discovered by Nerviano Medical Sciences researchers.
Entrectinib is an example of precision medicine, acting on a specific subset of related molecular targets: TRK, ROS and ALK kinases, all variously found in mutated, highly activated forms, in subsets of lung, colorectal, and other solid tumors. As part of its drug development programme, Nerviano Medical Sciences also initiated the clinical study of entrectinib at two institutes in Lombardy that are widely recognized as centres of excellence: the Niguarda Cancer Center (principal investigator: Prof. Salvatore Siena) and the National Cancer Institute of Milan (principal investigator: Prof. Filippo De Braud), with signs of antitumor activity already evident within the first few cohorts of patients treated with the drug. Further clinical development of the compound was expanded worldwide following its licensing to Ignyta Inc.
Thanks to the highly promising results observed during Phase I and Phase II clinical trials, Entrectinib received two important recognitions in 2017: "Breakthrough Therapy Designation" (BTD) from the American Food and Drug Administration (FDA) and "Priority Medicines" (PRIME) acknowledgement from the European Medicines Agency (EMA).
The AACR recognized this scientific achievement with presentation of a Certificate of Recognition and with the words "as a token of our appreciation for your valuable contribution."
"The data we have published – Dr. Ardini commented - were the amongst the most cited of all the AACR Journals Collection during the 2016. It is exciting the awareness of how important this award is for our work and for our value as a Research Centre."
Arturo Galvani, Ph.D., Head of Oncology Drug Discovery at Nerviano Medical Sciences added: “Entrectinib continues our heritage of bringing innovative drugs to cancer patients, and I am very happy to take this opportunity to congratulate all members of our organization for this further recognition of our science and of our drug discovery capabilities. Together, we in turn thank the AACR for its recognition of our work and we gratefully acknowledge its steadfast commitment to the sponsorship of innumerable initiatives in many facets of basic research, diagnostics, therapeutics, care-giver and patient involvement, all aimed at defeating the many diseases of uncontrolled cell growth which fall under the common label of cancer. We at Nerviano Medical Sciences are honoured to be involved in this world-wide effort.”
1Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.
Molecular Cancer Therapeutics 15:628-39. 2016
2Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.
Journal of Medicinal Chemistry 59:3392-408. 2016